Personnel announcement: Michael Pfeil appointed head of newly formed therapeutics operations unit at Merz Therapeutics
Frankfurt am Main, Germany, January 11, 2024 – Merz Therapeutics, a business of the Merz Group and leader in the field of neurotoxins, announces the promotion of Dr. Michael Pfeil to the role of Head of Therapeutics Operations, effective January 1st, 2024.
CEO Stefan König expressed his confidence in Michael’s capabilities, stating, “Michael’s extensive experience, unwavering commitment, and profound understanding of our business make him the ideal person to establish and lead our Therapeutics Operations. His leadership will undoubtedly drive us toward achieving operational excellence and strengthen our commitment to delivering better outcomes for more patients.”
In his new role, Michael reports directly to CEO Stefan Koenig. This appointment solidifies Michael’s position within the Merz Therapeutics executive team and underscores his integral role in driving operational excellence and innovative strategies.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com